A Resource for Healthcare and Social Services Professionals
This event is intended to provide eight hours of required training for providers seeking their buprenorphine waivers
This eight-hour course prepares physicians, nurse practitioners and physician assistants to prescribe buprenorphine to treat opioid use disorder in their office. The curriculum includes the science of addiction as a brain disorder, the pharmacology of buprenorphine, and the regulatory requirements around prescribing this medication. Attendees will learn to screen patients for treatment with buprenorphine and to manage the medication along with the patient's other medical needs in an office setting such as a primary care clinic. The course fulfills 8 hours of the training needed to obtain a waiver to prescribe buprenorphine. The Drug Addiction Treatment Act of 2000 (DATA 2000) requires physicians to complete 8 hours of approved training in order to be eligible for a waiver, and nurse practitioners and physician assistants to complete 24 hours.
A light breakfast and lunch will be provided.
Upon completion of this 8 hour training, the participants will be able to:
Physicians (MD, DO), Nurse Practitioners, and Physician Assistants
Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS).
American Academy of Addiction Psychiatry (AAAP) is the DATA 2000 sponsor for this training.
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
In support of improving patient care, this activity has been planned and implemented by Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Public Health and the Bureau of Substance Abuse Services and American Academy of Addiction Psychiatry. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
In 2019, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB).
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 8 (eight) Interprofessional Continuing Education credits for learning and change.
American Academy of Addiction Psychiatry designates this live course for a maximum of 8 (eight) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to 8 (eight) Nursing Contact Hours.
Physician Assistant Designation
American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Method of participation in the activity:
Partial credit will not be issued for this course. To be awarded full credit you must:
*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
AAAP's CE program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. The following PCSS-MAT, CPD Committee and AAAP staff members have reported that they have no commercial relationships relevant to the content of this activity to disclose: Stephen Wyatt, DO, Sanchit Maruti, MD, Thomas Penders, MD, Michael Goedde, MD, Kevin Sevarino, MD, Nitigna Desai, MD, Colleen Labelle, RN, Kathryn Cates-Wessel, Justina Andonian, Miriam Giles, Seth Acton, Marie Samson and Erin Waters.
Disclosure of Unlabeled Medication Use:
Recommendations involving clinical medicine are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.